WO2012175587A3 - Nouvel intermédiaire cristallin de céfopérazone - Google Patents

Nouvel intermédiaire cristallin de céfopérazone Download PDF

Info

Publication number
WO2012175587A3
WO2012175587A3 PCT/EP2012/061912 EP2012061912W WO2012175587A3 WO 2012175587 A3 WO2012175587 A3 WO 2012175587A3 EP 2012061912 W EP2012061912 W EP 2012061912W WO 2012175587 A3 WO2012175587 A3 WO 2012175587A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
pharmaceutical use
cefoperazone
crystalline
crystalline cefoperazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/061912
Other languages
English (en)
Other versions
WO2012175587A2 (fr
Inventor
Harold Monro Moody
Claudia Cusan
Edwin Gerard Ijpeij
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centrient Pharmaceuticals Netherlands BV
Original Assignee
DSM Sinochem Pharmaceuticals Netherlands BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM Sinochem Pharmaceuticals Netherlands BV filed Critical DSM Sinochem Pharmaceuticals Netherlands BV
Priority to EP12729575.6A priority Critical patent/EP2723881A2/fr
Priority to US14/128,818 priority patent/US20150112057A1/en
Priority to CN201280031051.XA priority patent/CN103635586A/zh
Publication of WO2012175587A2 publication Critical patent/WO2012175587A2/fr
Publication of WO2012175587A3 publication Critical patent/WO2012175587A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C12P35/04—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin by acylation of the substituent in the 7 position

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline d'un intermédiaire de céfopérazone de formule (1) et un procédé de préparation de celle-ci par la condensation enzymatique d'un noyau β-lactame 3'-thiosubstitué avec un dérivé de phénylglycine.
PCT/EP2012/061912 2011-06-23 2012-06-21 Nouvel intermédiaire cristallin de céfopérazone Ceased WO2012175587A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP12729575.6A EP2723881A2 (fr) 2011-06-23 2012-06-21 Nouvel intermédiaire cristallin de céfopérazone
US14/128,818 US20150112057A1 (en) 2011-06-23 2012-06-21 Novel crystalline cefoperazone intermediate
CN201280031051.XA CN103635586A (zh) 2011-06-23 2012-06-21 结晶头孢氧哌唑中间体、其制备方法及其制药用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11171178.4 2011-06-23
EP11171178 2011-06-23
EP12163100 2012-04-04
EP12163100.6 2012-04-04

Publications (2)

Publication Number Publication Date
WO2012175587A2 WO2012175587A2 (fr) 2012-12-27
WO2012175587A3 true WO2012175587A3 (fr) 2013-03-28

Family

ID=46354314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/061912 Ceased WO2012175587A2 (fr) 2011-06-23 2012-06-21 Nouvel intermédiaire cristallin de céfopérazone

Country Status (3)

Country Link
EP (1) EP2723881A2 (fr)
CN (1) CN103635586A (fr)
WO (1) WO2012175587A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113250A (zh) * 2013-03-08 2013-05-22 华北制药集团先泰药业有限公司 一种d-对羟基苯甘氨酸甲酯的制备方法
CN117105957A (zh) * 2023-07-21 2023-11-24 国药集团威奇达药业有限公司 头孢哌酮酸的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946003A (en) * 1974-08-20 1976-03-23 Eli Lilly And Company Hydroxy substituted phenylglycylamido-3-heterocyclic thiomethyl cephalosporins
EP0523585A2 (fr) * 1991-07-15 1993-01-20 BIOCHEMIE Gesellschaft m.b.H. Améliorations quant à la production de bêta-lactames
EP1394262A1 (fr) * 2002-08-30 2004-03-03 Bioferma Murcia, S.A. Procédé enzymatique de préparation de composés de bêta-lactame

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5343597B1 (fr) 1970-12-25 1978-11-21
JPS5548797B1 (fr) 1971-04-02 1980-12-08
JPS51133488A (en) 1975-05-14 1976-11-19 Shionogi & Co Ltd Process for producing antibiotics enzymatically
DE2600880C2 (de) 1976-01-12 1984-09-13 Toyama Chemical Co. Ltd., Tokio / Tokyo Cephalosporinverbindungen
PT83746B (pt) 1985-11-15 1988-08-17 Gist Brocades Nv Processo para a preparacao de novos biocatalisadores imobilizados e para a producao de etanol por fermentacao
ES2090031T3 (es) 1988-04-26 1996-10-16 Gist Brocades Nv Proceso para la preparacion enzimatica de beta-lactamas.
EP0537255B1 (fr) 1990-07-04 2006-02-15 DSM IP Assets B.V. Procédé de préparation de beta-lactames
IT1243800B (it) 1990-08-28 1994-06-28 Sclavo Spa Procedimento migliorato per la preparazione di cefalosporine
ES2059285T1 (es) 1991-12-19 1994-11-16 Novo Nordisk As Un metodo mejorado para la preparacion de ciertos antibioticos beta-lactamicos.
US6048708A (en) 1994-07-18 2000-04-11 Gist-Brocades B.V. Process for preparation of β-lactams at constantly high concentration of reactants
ES2144139T3 (es) 1994-08-12 2000-06-01 Dsm Nv Genes de la penicilina g-acilasa mutados.
ATE204580T1 (de) 1995-02-02 2001-09-15 Dsm Nv Verfahren zur gewinnung von cephalexin
EP0839192B1 (fr) 1995-07-18 2008-12-10 DSM IP Assets B.V. Penicilline g acylase immobilisee amelioree
NL1006266C2 (nl) 1997-06-10 1998-12-14 Chemferm Vof Werkwijze voor de bereiding van ampicilline.
NL1007302C2 (nl) 1997-10-17 1999-04-20 Dsm Nv Werkwijze voor de bereiding van een ß-lactam antibioticum.
NL1010506C2 (nl) * 1998-11-06 2000-05-09 Dsm Nv Werkwijze voor de bereiding van bêta-lactam antibiotica.
WO2002085914A2 (fr) 2001-04-19 2002-10-31 Bioferma Murcia, S.A. Procede permettant de preparer des derives d'acide 3-cephalosporanique a l'aide de derives d'acide cetonique alpha
KR20040075042A (ko) 2001-12-27 2004-08-26 디에스엠 아이피 어셋츠 비.브이. β-락탐 항생제의 제조 방법
WO2005000367A2 (fr) 2002-08-07 2005-01-06 Steris Inc. Systeme de decontamination destine au courrier et a d'autres articles
WO2006069984A2 (fr) 2004-12-27 2006-07-06 Dsm Ip Assets B.V. Procede de synthese de cefaclor
WO2008110529A1 (fr) 2007-03-09 2008-09-18 Dsm Ip Assets B.V. Procédé pour la préparation d'esters méthyliques d'acides aminés
KR101444492B1 (ko) 2007-03-09 2014-09-24 디에스엠 시노켐 파마슈티칼스 네덜란드 비.브이. 베타-락탐 화합물의 제조 방법
HUE036302T2 (hu) * 2008-12-23 2018-07-30 Dsm Sinochem Pharm Nl Bv Mutáns penicillin-G-acilázok

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946003A (en) * 1974-08-20 1976-03-23 Eli Lilly And Company Hydroxy substituted phenylglycylamido-3-heterocyclic thiomethyl cephalosporins
EP0523585A2 (fr) * 1991-07-15 1993-01-20 BIOCHEMIE Gesellschaft m.b.H. Améliorations quant à la production de bêta-lactames
EP1394262A1 (fr) * 2002-08-30 2004-03-03 Bioferma Murcia, S.A. Procédé enzymatique de préparation de composés de bêta-lactame

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *
DUNN G L ET AL: "Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK & F 60771)", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 29, no. 1, 1 January 1976 (1976-01-01), pages 65 - 80, XP008157551, ISSN: 0021-8820 *

Also Published As

Publication number Publication date
CN103635586A (zh) 2014-03-12
WO2012175587A2 (fr) 2012-12-27
EP2723881A2 (fr) 2014-04-30

Similar Documents

Publication Publication Date Title
WO2011138281A3 (fr) Procédé de production de dithiine-tétracarboxy-diimides
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
WO2012156998A3 (fr) Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron
AP3589A (en) A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
WO2013098833A3 (fr) Procédés et intermédiaires destinés à la préparation de rivaroxaban
MX348654B (es) Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion.
WO2008155615A3 (fr) Procédé perfectionné pour la préparation d'un antibiotique de la famille des céphalosporines
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
WO2010140765A3 (fr) Nouveau procédé de préparation de rosuvastatine, composés intermédiaires utiles pour préparer de la rosuvastatine, et procédé de préparation correspondant
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
WO2013014665A8 (fr) Composés intermédiaires et procédé pour la préparation de lurasidone et de sels de celle-ci
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
WO2011157390A3 (fr) Procédé de préparation de composés 3-(1-amino-2-methylpentane-3-yl)phényle substitué
WO2012131707A3 (fr) Nouvelle forme cristalline de bortezomib, son procédé de préparation et composition pharmaceutique l'utilisant
HK1205095A1 (en) Methods and intermediates for preparing pharmaceutical agents
WO2012038979A3 (fr) Procédé de préparation d'ertapénem
WO2010079045A3 (fr) Nouveaux sels
WO2014097272A3 (fr) Procédé de production de (s,s)-6-benzyloctahydro-1h-pyrrolo[3,4-b]- pyridine, un intermédiaire pour dérivés d'azabicyclopyridine
WO2012063115A3 (fr) Procédé de préparation de rosuvastatine calcique via un nouvel intermédiaire amine
WO2013072938A3 (fr) Procédé amélioré pour la préparation de roflumilast
CA2862757A1 (fr) Procede de fabrication d'un derive de naphthyridine
WO2013092672A3 (fr) Procédé pour la production recombinante de labyrinthopeptines et dérivés fonctionnels de celles-ci
WO2012134103A3 (fr) Dérivé à base d'ester de norbornène, son procédé de fabrication et ses utilisations
WO2013046233A3 (fr) Procédé de préparation d'acétate d'octréotide
WO2011157670A3 (fr) Nouveau procédé

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12729575

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14128818

Country of ref document: US